Short answer
Jade Biosciences, Inc. (JBIO) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$40M
- −1503.2% YoY
- EPS (diluted)
- −$0.57
- −533.3% YoY
Source: XBRL data from the Jade Biosciences, Inc. (JBIO) Q1 2026 10-Q on SEC EDGAR. USD.
Jade Biosciences, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No explicit new or changed risk-factor language provided; excerpt omits the actual Risk Factors section
- Liquidity risk: cash and investments totaled $311.3 million at March 31, 2026, funding operations for at least twelve months
- Clinical development risk: JADE101 and JADE201 require significant preclinical, clinical, manufacturing, and regulatory expenditures
- Regulatory risk: product candidates require regulatory approval before commercialization, with no assurance approvals will be obtained
- Market risk: no product revenue generated, leaving continued dependence on equity offerings for financing કામગીરી
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Jade Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.